{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:03Z","timestamp":1747181163162,"version":"3.40.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:p>Although true treatment resistant hypertension is relatively rare (about 7.3% of all patients with hypertension), optimal control of blood pressure is not achieved in every other patient due to suboptimal treatment or nonadherence. The aim of this study was to compare effectiveness, safety and tolerability of various add-on treatment options in adult patients with treatment resistant hypertension The study was designed as multi-center, prospective observational cohort study, which compared effectiveness and safety of various add-on treatment options in adult patients with treatment resistant hypertension. Both office and home blood pressure measures were recorded at baseline and then every month for 6 visits. The study cohort was composed of 515 patients (268 females and 247 males), with average age of 64.7\u2009\u00b1\u200910.8 years. The patients were switched from initial add-on therapy to more effective ones at each study visit. The blood pressure measured both at office and home below 140\/90\u2009mm Hg was achieved in 80% of patients with add-on spironolactone, while 88% of patients taking this drug also achieved decrease of systolic blood pressure for more than 10\u2009mm Hg from baseline, and diastolic blood pressure for more than 5\u2009mm Hg from baseline. Effectiveness of centrally acting antihypertensives as add-on therapy was inferior, achieving the study endpoints in &lt;70% of patients. Adverse drug reactions were reported in 9 patients (1.7%), none of them serious. Incidence rate of hyperkalemia with spironolactone was 0.44%, and gynecomastia was found in 1 patient (0.22%). In conclusion, the most effective and safe add-on therapy of resistant hypertension were spironolactone alone and combination of spironolactone and a centrally acting antihypertensive drug.<\/jats:p>","DOI":"10.1097\/md.0000000000033941","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T15:14:18Z","timestamp":1685718858000},"page":"e33941","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Results of the trycort: Cohort study of add-on antihypertensives for treatment of resistant hypertension"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-8828","authenticated-orcid":false,"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"first","affiliation":[{"name":"University of Kragujevac, Faculty of Medical Sciences and University Clinical Center, Kragujevac, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sini\u0161a","family":"Stojkovi\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Center of Serbia, Cardiology Clinic, and Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milovan","family":"Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, and Faculty of Medicine Novi Sad, University of Novi Sad, Sremska Kamenica, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomislav","family":"Kosti\u0107","sequence":"additional","affiliation":[{"name":"University Clinical Center Ni\u0161, and Medical Faculty, University of Ni\u0161, Ni\u0161, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Zdravkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Clinical Hospital Center Be\u017eanijska kosa, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slavica","family":"Radovanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinical Hospital Center Dr Dragi\u0161a Mi\u0161ovi\u0107, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radosava","family":"Cvjetan","sequence":"additional","affiliation":[{"name":"Clinical Hospital Center Zemun, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nenad","family":"Ratkovi\u0107","sequence":"additional","affiliation":[{"name":"Military Medical Academy, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislav","family":"Rihor","sequence":"additional","affiliation":[{"name":"Institute for Rehabilitation, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejan","family":"Spiroski","sequence":"additional","affiliation":[{"name":"Institute for Rehabilitation, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Stankovi\u0107","sequence":"additional","affiliation":[{"name":"General Hospital Leskovac, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko","family":"An\u0111elkovi\u0107","sequence":"additional","affiliation":[{"name":"Galenika a.d., Belgrade, Serbia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Goci\u0107 Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Galenika a.d., Belgrade, Serbia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension.","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients.","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.archger.2017.07.018","article-title":"A systematic review of hypertension outcomes and treatment strategies in older adults.","volume":"73","author":"Kirk","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines.","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension.","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2215\/CJN.06180616","article-title":"Recognition and management of resistant hypertension.","volume":"12","author":"Braam","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13318-022-00760-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of esaxerenone, a novel mineralocorticoid receptor antagonist: a review.","volume":"47","author":"Jankovi\u0107","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","article-title":"Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials.","volume":"39","author":"Liu","year":"2017","journal-title":"Clin Exp Hypertens"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","article-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension.","volume":"233","author":"Zhao","year":"2017","journal-title":"Int J Cardiol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0042-100912","article-title":"Recent developments and controversies in the treatment of resistant hypertension.","volume":"124","author":"K\u00fchl","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"Suppl 1","key":"R11-20250504","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.nephro.2016.01.003","article-title":"Carotid barostimulation in the treatment of resistant hypertension.","volume":"12","author":"Rossignol","year":"2016","journal-title":"Nephrol Ther"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrcardio.2015.96","article-title":"Carotid baroreflex activation therapy for resistant hypertension.","volume":"12","author":"Victor","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/HJH.0000000000002933","article-title":"European society of hypertension position paper on renal denervation 2021.","volume":"39","author":"Schmieder","year":"2021","journal-title":"J Hypertens"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40256-017-0224-5","article-title":"A systematic review of add-on pharmacologic therapy in the treatment of resistant hypertension.","volume":"17","author":"Tataru","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","article-title":"Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials.","volume":"25","author":"Wang","year":"2016","journal-title":"Heart Lung Circ"},{"key":"R16-20250504","first-page":"e484","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American heart association task force on clinical practice guidelines.","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R18-20250504","first-page":"260","article-title":"A questionnaire for rating health-related quality of life.","volume":"60","author":"Jankovi\u0107","year":"2021","journal-title":"Zdr Varst"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment).","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension.","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone.","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1345\/aph.1P338","article-title":"Spironolactone management of resistant hypertension.","volume":"44","author":"Marrs","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten antiproteinuric properties of diuretics.","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11906-015-0578-5","article-title":"Quality of life in treatment-resistant hypertension.","volume":"17","author":"Carris","year":"2015","journal-title":"Curr Hypertens Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:10:06Z","timestamp":1746324606000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":25,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033941","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}